INTRODUCTION
Resistance of tumor cells to anticancer drugs is mainly due to the activity of multidrug resistance proteins belonging to the membrane ABC transporters superfamily. These proteins are able to actively transport drugs out of the cell at the expense of the hydrolysis of Mg-ATP [1, 2] . Several MDR transporters appear to function as phospholipid or cholesterol translocases and to be involved in endogenous lipid transport routes [3, 4] . Elucidation of the molecular mechanism of MDR transporters has therefore both biomedical and fundamental relevance.
The P-glycoprotein, product of the mdr1 gene in humans, is the most studied multidrug transporter.
This transmembrane ATPase is able to extrude chemotherapeutic drugs and other molecules with a broad but defined specificity. Several lines of data suggest that at least part of the drugs is transported from the inner membrane leaflet rather than from the intracellular aqueous phase [5] . Phospholipid and cholesterol transport by P-gp have been reported [6, 7] . P-glycoprotein has an overall molecular architecture similar to all ABC transporters. It is made of two halves, each consisting of a transmembrane domain (TMD) and a cytoplasmic nucleotide binding domain (NBD). In P-gp, both halves are carried by a single polypeptide chain and have highly homologous sequences. Each TMD consists of 6 contiguous transmembrane helices and is linked to its corresponding NBD. The 2 NBDs share a large homology with those of other ABC transporters and contains several consensus structural motifs involved in ATP hydrolysis.
Progress in understanding the mechanism of drug transport is still hampered by the lack of detailed information upon the three-dimensional structure of P-gp. However, important progresses have been made recently in this regard. Mutagenesis, photoaffinity labeling and crosslinking studies have identified the residues involved in the drug binding site which are located in the TMDs (for reviews see
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MATERIALS AND METHODS
Sequence alignments and secondary structure prediction.
All sequences were obtained from the Swissprot-TREMBL database. Sequence alignments were generated automatically with the ClustalX program [16] and optimized manually. Secondary structure prediction of the 3 intracellular domains of P-gp as well as transmembrane helices prediction were performed with the PHD server (http://cubic.bioc.columbia.edu/predictprotein/predictprotein.html) using alignments of all ABC transporters having more than 40 % homology with P-gp in the regions to predict. Motif search in the Swissprot-TREMBL database was performed with the Protein Information Resource server (http://pir.georgetown.edu/pirwww/search/patmatch.html).
Homology modeling
Graphical representations of molecular structures were done with Molscript [17] , Molmol [18] and Raster3d [19] . Protein structure files manipulations and modifications were done with Whatif [20] Homology modeling was performed with the Modeller 6.2 software [21] . The template structure was based on the MsbA dimer PDB structure (1JSQ) which contains only the coordinates of α carbons [10] .
It was necessary to take into account the fact that several sequence stretches of P-gp have no counterparts in the MsbA structure. This includes regions that exist both in PGP and MsbA but are not resolved in the MsbA structure (for each MsbA monomer: residues 208-237 in ICD2, residues 343-408 and 565-576 in the NBD) as well as regions that correspond to extra sequences stretches in P-gp (Pgp residues 76-84 and 97-109 in EC1, 255-284 in ICD2, 896-987 in ICD5 and smaller insertions).
Secondary structure prediction using PHD indicated that part of these sequences stretches, belonging to the TM domains of P-gp have an helical conformation. These correspond to helical extensions of TM2 and of the two helices of the ICD2 and ICD5. Cα atoms corresponding to canonical α-helical geometry were thus added to the template in order to extend these helices with an orientation dictated by the geometry of the residue at their extremity. Secondary structure prediction also indicated that the other P-gp insertion stretches of the TM domain have a loop (i.e. non regular) conformation. These were thus left to be optimized in the second stage of the homology modeling procedure. The missing portions of the 2 NBD were added to the template as the corresponding domains of the TAP1 NBD structure (PDB file 1JJ7) [22] after aligning manually both nucleotide domains. The largest addition was the 505-580 region of the TAP1 NBD which corresponds to a 3 strands-helix-2 strands-helix motif (β1-β2-β3-α1-β4-β5-α2, in the usual NBD nomenclature, see [22] ). The third strand β3 of this motif was cut off at its C-terminal end and reoriented by ca 20° around its N-terminal residue in order to be included in a beta sheet with β6, β7 and β8 of the MsbA NBD as is current in all known ABC transporter NBDs. All connecting loops were first closed manually and left to be optimized in the second stage of the homology modeling procedure. The conformation of the Walker A motif was not modified by this manipulation. A second addition to the template was a two helix motif (α8-α9, residue 729-740 of the TAP1 NBD) which was connected at the C-terminal of each of the template NBD, its orientation being dictated by the backbone conformation of the C-terminal residues of the MsbA monomer PDB structure. The 627-693 linker region of P-gp was not considered in the present study since it apparently bears no structural relevance to function apart from a flexibility requirement [23] .
The first stage of modeling was performed with the "model" routine of Modeller 6.2 using the modified MsbA template and the alignment of MsbA and P-gp as input. Helix, strand and sheet restraints corresponding to the secondary structure of MsbA [10] as well as to that of predicted helical regions and inserted TAP1 portions [22] were imposed. 20 structures were generated among which one was selected which corresponded to low restraints violations and to an adequate bond angles, bond lengths and backbone dihedrals stereochemistry, as checked with Whatif. In a second stage, the Modeller 6.2 "loop" routine [24] was used to optimize the conformations of loops. The small loops (<5 residues) were optimized in a single calculation in which 20 structures were generated. The 20 structures were superimposed, those having minor loop conformations were discarded and the structure with the best bond and angle stereochemistry of the loops was selected. Each of the larger loops was then optimized separately again selecting each time the best among 20 generated structures after eliminating structures with minor loop conformations and evaluating stereochemical quality. Several abnormal ω angles, steric clashes and abnormal bond lengths and bond angles were corrected using Whatif, respectively by reconstructing the residue from its α carbon, by conformational search debumping and by atom displacement refinement. This procedure was deemed preferable to further energy minimization which often has detrimental effects on packing. Procheck [25] analysis of the modeled P-gp structure indicated that the quality of the Ramachandran plot (97.6% of the backbone angles in the allowed regions) and other main chain or sidechain geometric properties were equivalent to those of an experimental structure with a 0.25 nm resolution. The modeled structure is such that no 8 polar sidechain is located in the region expected to be in contact with the hydrophobic part of the bilayer confirming the validity of the alignment.
Residue contact and molecular surface analyses
Identification of residues corresponding to the TMD-NDB interfaces and to the monomer-monomer interface in MsbA was performed using Whatif. First an all-atom structure of MsbA was generated from the α carbon coordinates using the "catoal" function of Whatif. Then interface residues were identified as those having a less than 0.45 nm center to center distance between sidechain atoms. This relatively large cutoff was chosen in view of the uncertainties inherent to the all-atom modeled structure.
Interface residues involving the ICDs and NBDs in the modeled P-gp structure were identified similarly using a distance cutoff of 0.4 nm. Analysis of sidechain contribution to the P-gp chamber surface was performed with Grasp [36] . Surface potential was calculated with Molmol using a 100 mM ionic strength and dielectric constants of 2 and 80 for protein and solvent.
RESULTS
MsbA and P-gp sequence and secondary structure homology
In order to evaluate the validity of MsbA as a structural model for P-gp we have first examined in detail the sequence and secondary structure homology of the two proteins. The alignment of P-gp with two MsbA monomers is shown in Fig. 1 . The alignment yields respectively a 31 and 30 % identity of MsbA to the two P-gp transporter halves. Recent studies have demonstrated that a sequence identity higher than 25% between 2 proteins is indicative of similar 3D structures [27] . Several conserved sequence motifs are apparent in the regions corresponding to the extracellular domains of as well as in the IC2-TM4 and IC5-TM10 regions. In particular there is a conserved sequence motif encompassing a 29 residue stretch in the first intracellular region. Database search indicated that this motif corresponds to
This motif appears to be present in 80 ABC transporter sequence in the Swissprot-TREMBL database. The sequence families correspond to MsbA, ValA (known to be functionally similar to MsbA, see [28] ), YvcC [11] , the drug/lipid transporters LmrA [29] and HorA [30] , several antibiotic resistance transporters from Staphylococcus aureus [31] , a few uncharacterized transporters from extremophiles, an ABC transporter subfamily from plants, the mammalian transporter ABC8 involved in phospholipidcholesterol transport [32] , as well as 35 P-gp like sequences including those of all known mammalian P-gps, phosphatidylcholine translocases and bile salt export pumps and those of MDR proteins from Drosophila melanogaster, Caenorhabditis elegans and other organisms. This motif was not found in any bacterial or eucaryotic transporter known not to be involved in lipid or drug transport.
The structural similarity between MsbA and P-gp was also investigated at the secondary structure level. Transmembrane helix predictions yielded limits for P-gp that are qualitatively consistent with those of the MsbA structure. A crucial test is the secondary structure prediction of the intracellular regions of P-gp. Indeed an important aspect of the MsbA structure is the fact that all 6 transmembrane helices of the monomer are connected on the intracellular side to largely helical segments (ICD1, ICD2 and ICD3) that also interact with the NBD [10] . The result of secondary structure prediction for the corresponding regions of P-gp is shown in Fig. 1 . It indicates that the predicted secondary structure in the intracellular regions of P-gp is largely helical. The residue to residue agreement between the predicted secondary structure of P-gp and the experimental secondary structure of MsbA in the intracellular region is 71%. Considering that the accuracy of such secondary structure prediction is 72% [33] , this shows that the secondary structure of the intracellular region of P-gp is highly similar to the corresponding regions of MsbA.
We have also attempted to evaluate whether the relative topology and the interactions between the TMD and NBD in each P-gp half is comparable to that found in the MsbA monomer structure. For this purpose, the residues pairs involved in TMD-NBD contacts in MsbA were identified and their conservation in P-gp was evaluated (Table 1 ). In the crystallographic MsbA structure, we found 13 residue pairs involved in the interaction between the NBD and the ICD1 of the TMD (note that this represents only a part of the actual contact regions since portions of ICD2 and of the NBD are not resolved in this structure). Respectively 9 and 7 of these 13 residue pairs are either conserved or replaced by homologous residue pairs in the 2 P-gp halves. This is a strong indication that the interface between the TMD and the NBD and therefore their relative topology are conserved between MsbA and P-gp.
These data indicate that the 3D structure of each P-gp half is similar to that of the MsbA monomer (excluding a few insertions of limited length, see below). We have also investigated whether the association of the 2 P-gp halves is comparable to the MsbA dimer. As shown in Fig. 2A , the open dimer structure of MsbA mainly involves interactions between residues of TM2 of each monomer and TM5 and TM6 of the other monomer. A few mutual interactions between the EC1 and EC3 loops of each monomer also contribute. Fig. 2B shows alignments of the corresponding regions for representative sequences of several subfamilies of known or putative lipid-drug bacterial and eucaryotic ABC transporters (which all carry the above mentioned intracellular sequence motif). It appears that no exact conservation of specific residues occurs among transporters in these regions.
Surprisingly, such absence of exact residue conservation is current even between MsbA and YvcC which both possess the same open dimer structure [11] , as well as between MsbA and ValA which have a similar function [28] . This indicates that the characteristic interactions of the open dimer structure are not dependent on exact conserved sequence motifs. On the other hand, among transporter types, there is a definite trend toward conservation of two types of homologous residue: hydrophobic (aromatic or aliphatic) residues and small size residues (G, S, T, C, P). For all sequences, the involved regions of the TM helices are characterized by groups of hydrophobic residues separated by small sidechain residues. Recent studies indicate that such motifs are involved in the association of TM helices [34] [35] [36] [37] [38] . Furthermore for each transporter type these sequence stretches appear highly conserved among homologous sequences (i.e. between 78 and 100 %). This suggests (without proving it) that for each transporter, including P-gp, these regions may be involved in similar interactions, namely association of the 2 transporter halves into an open structure as in MsbA.
Homology modeling of P-gp from MsbA
The data described above demonstrate that the 3D structure of each P-gp halves is largely similar to that of the MsbA monomer. These data also suggest that the MsbA open dimer structure may be also valid for P-gp. As a consequence, it seems justified to attempt to predict the 3D structure of P-gp by homology modeling using the MsbA crystallographic structure as a template. Several regions of the Pgp sequence cannot be modeled from the MsbA PDB coordinates. First, three regions of the MsbA structure are not resolved in the crystallographic structure. These include a part of the ICD2 region of the TMD as well as two regions in the NBD. In addition, there are several insertion stretches in the Pgp sequence that have no counterpart in the MsbA sequence and structure, including parts of the EC1 and EC4 regions. The missing regions of the NBD were taken from the crystallographic structure of the highly homologous NBD domain of the ABC transporter TAP1 [32] (TAP1 was chosen because its NBD has the highest homology and the closest secondary structure to those of P-gp). For this purpose the TAP1 NBD was aligned with that of the MsbA NBD. While we have performed this structural alignment manually, it appears to be very similar to the automatically generated alignment between MsbA and the HisP NBD domain shown in [22] . Secondary structure prediction of P-gp ( Fig. 1) indicated that the missing or non-aligned stretches of EC1, ICD2 and ICD5 could in part be modeled as helical regions. The remaining regions have no regular secondary structure and were modeled as loops. The linker region of P-gp was not modeled in the present study since it has no counterpart in structurally solved ABC transporters and apparently bears no structural relevance to P-gp function apart from a flexibility requirement [23] . Fig. 3 shows the modeled structure of P-gp. In spite of sequence differences between transporter halves, the organization of the molecule is relatively symmetric. The asymmetry is limited to difference in length of several helices on the extracellular side (in particular TM2 and TM7) and to different conformations of extracellular loops between the two halves. Such differences do not affect the interface between the two halves. A new information contained in the modeled P-gp structure is the inclusion of several regions that were not present in the MsbA structure due to crystallographic disorder. Of particular interest is the inclusion of a region located on one side and on the facing region of each NBD and containing the Walker A motif. The separation between the two completed NBDs is 3.3 nm. Each Walker A motif is located on the side of its NBD. The modeling of these regions and of a missing region of ICD2 and ICD5 allows us to draw a more complete picture of mutual interactions of the intracellular domains and the NBDs (Fig. 3D ). Earlier studies have emphasized the possible importance in energy coupling of relative motions of two portions of the NBD: the core domain (which contains the ATP binding site) and the α-domain (i.e. helices α3 to α5) [17, 39] . These two domains are linked by stretches of high conformational mobility, one being the conserved Q-loop. Interestingly, in the modeled P-gp structure, the three ICDs of each transporter half have contacts with distinct and defined regions of the NBD. ICD1 interacts primarily with the α-domain and the Q-loop with only a limited interaction with the core. ICD2-NBD contacts occur mainly with the Q-loop and the core domain.
Both ICD1 and ICD2 have limited contacts with the Walker A motif. IDC3 interactions involve solely the core domain. Additionally all three ICDs interact together. There is a remarkably complex structural role
conserved residues of this motif appear to be involved in stabilization of ICD1 (R148, I155, L171, and D178), interactions with ICD2 (T173, R174) and ICD3 (F163, D164) as well as contact with the α-domain (F152, W162), the Q loop (W162, L171) and the core domain (F163) Similar interactions occur for the C-terminal half.
Chamber structure
An essential aspect of the MsbA structure which is reflected also in the modeled P-gp structure is the presence of an internal chamber delimited by the association of the two TMDs and their associated ICDs. The 6 TM helices of each transporter half and their linked intracellular helices form an irregular half-barrel ( Fig. 3 A and C) . The two half-barrels interact only by their extracellular parts thereby forming a chamber which is open to both the inner bilayer leaflet and the intracellular aqueous phase.
The chamber is closed on the extracellular side by the extracellular loops ( Fig. 3B and 4B ). As clearly visible in Fig. 4 (A-C) in which the molecular surface has been colored according to secondary structure elements as in Fig. 3 , only 8 TM helices contribute importantly to the chamber structure. The contribution of TM1, TM6, TM7 and TM12 is minimal. In particular, the orientation of TM6 and TM12 precludes their participation to the chamber. All 6 ICDs, but mostly ICD3 and ICD6 contribute to the chamber in its intracellular part. The interior volume of each of the two lobes of the chamber is smaller than for MsbA. This is due to the presence of numerous bulky aromatic sidechains (see below). The charge inside the chamber is also significantly different. While the MsbA chamber has an overall highly positive surface potential [10] , the P-gp chamber displays a much more reduced charge distribution with patches of both positive and negative surface potential (Fig. 4D) . Indeed, the surface region of the MsbA chamber that corresponds to the cytoplasmic bilayer leaflet and aqueous space contains contributions from 16 positive and only one negative sidechains. In comparison, the corresponding region of the P-gp chamber contains 6 positive and 3 negative sidechains.
The 122 residues contributing to the molecular surface of the chamber borders and interior are indicated in Fig. 5 . Interestingly, mutations of several of these residues have been shown to impair transport or drug resistance. These include Q132 [40] , N842 [41] , Y953 [42, 43] ,F957 [43] , F983 [44] , As already mentioned, a striking feature of the P-gp chamber is the presence of numerous aromatic
sidechains. There appears to be 20 aromatic residues contributing to the chamber internal surface which mostly occupy equivalent positions on the 2 halves. In particular TM5 and TM11 contribute respectively 5 and 4 aromatic residues to the chamber. As shown in Fig.4E , these aromatic residues are mainly located on the periphery of each side of the chamber thereby reducing its internal volume.
We have studied the conservation of the 122 residues of the chamber surface among P-gps of various organisms (abcb1 gene) and among the relatively homologous phosphatidylcholine translocase (abcb4 gene) and bile salt export pump (abcb11 gene) subfamilies [45] . As indicated in Table 2 , the extent of conservation and homology of the 122 chamber residues is significant. Some residues are heterologous, i.e. different between subfamilies but conserved within each subfamily and therefore are likely to be associated with the binding selectivity of each subfamily. Compared to other residue types, the conservation of the 20 aromatic residues of the chamber is very high. These are completely conserved or replaced by homologous aromatic residues in P-gp and phosphatidylcholine translocase subfamilies and also conserved to a large extent in the bile salt export pump subfamily. This suggests an important role for these residues in the transport process for P-gp-like ABC transporters.
In Fig. 5 , we have also indicated the residues which have been previously associated with the drug binding site of P-gp, i.e. residues that are labeled by reactive drugs [42, [46] [47] [48] or correspond to mutations affecting the selectivity of transport or drug resistance [49] [50] [51] [52] [53] [54] [55] (although in the second case the effect may be indirect). While a few of these residues contribute to the chamber, the majority are distinct although generally located in similar regions of the P-gp polypeptide chain. This suggest that the chamber although involved in drug binding is distinct from the drug binding site per se i.e. the site where drugs are bound just before getting transported.
DISCUSSION.
Validity of MsbA as a structural template for P-gp.
The determination of the crystallographic structure of E. Coli MsbA [10] has been the focus of recent interest due to the significant sequence homology and functional similarity to P-gp. Furthermore, the fact that this open structure has also been found for YvcC using a very different type of crystal [11] indicates that this organization is relevant for several bacterial drug ABC transporters. The presence of
an internal chamber open to one bilayer leaflet provides an appealing structural basis for one of the most intriguing aspects of lipid/drug ABC transporters, namely the fact that transport can occur from a membrane-bound location of the drug or lipid [5] . Evidence for the occurrence of such a chamber for P-gp has been obtained by electron microscopy 5 [9] . It thus appears important to determine whether
MsbA is an adequate structural model in P-gp.
In this regard, the sequence homology and sequence-structure relationship studies presented here indicate unambiguously that each of the two halves of P-gp has a 3D structure which is very close to that of the crystallographic MsbA monomer. Of course this does not preclude the possibility that both the MsbA monomer and the two P-gp halves might adopt other conformations (see below). Our data also suggest that P-gp might possess an association state of its two halves that is similar to the MsbA dimer. Here the data is not clear-cut since the dimer interface does not seem to be associated with strictly conserved sequence motifs, even between MsbA and YvcC that are known to share the same open structure. However, in the corresponding sequence regions, there is an overall conservation over several families of lipid-drug transporters of residue types that are known to be associated with transmembrane helix oligomerization. This is a good suggestion of the conservation of this region as an interface between transporter halves, although this does not constitute a definitive proof.
Accuracy of homology modeling
In view of this high structural homology we have attempted to obtain a 3D structure for P-gp by homology modeling from the MsbA structure. The accuracy of homology-modeled protein structures is currently limited by three factors [56] : (1) the validity of the sequence alignment of the target to the template; (2) the accuracy of the modeling of inserted or non-aligned regions; (3) the quality of sidechain modeling. In our alignment of MsbA and P-gp we have attempted to maximize the homology between the two sequences. However, it is still possible that the "true" alignment does not correspond to the highest homology. Also, we have attempted to model the missing regions of the NBD from the homologous structure of the TAP1 NBD using a structural alignment similar to another obtained recently [15] . A similar approach has been used recently to model missing parts of MsbA [57] . Several missing short helical regions of P-gp were modeled from secondary structure predictions, i.e. only with 72% accuracy [33] . The P-gp unaligned loops that we have modeled are at most 9 residues long, a value which represent the upper limit of reasonably accurate loop modeling [24] . The conformation of sidechains might be approximate especially since the starting MsbA structure is an α carbon model.
However, sidechain conformation is largely determined by the local secondary structure [58] .
Altogether it seems probable that we have built a qualitatively accurate model of P-gp from MsbA.
TMD-ICD-NBD interactions in the modeled P-gp
The modeled P-gp structure has allowed us to get an insight into structural relationship between the TMDs and NBDs that seem important for transport. Several studies have suggested that energy transduction after ATP hydrolysis by the NBD is mediated by motion of the α domain relative to the core domain and by conformational changes of the Q loop [17, 39] Mutations in ICD1 are known to abolish multidrug resistance and drug-stimulated ATPase activity [40] .
The conservation of this motif among numerous drug/lipid ABC transporters suggests a common mechanism of transport. This motif also contains the so-called L-loop, a 6 residue stretch which was emphasized in the BtuD structure and seems to be partially conserved in several ABC transporters [13] . This stretch appears to be in contact with the same NBD secondary structure elements in both Pgp and BtuD, namely α1, α2 and α3, although with a different orientation. This suggests a common mode of coupling of transport to ATP hydrolysis in different types of ABC transporters in spite of different transport mechanisms.
Properties of the P-gp chamber
The modeled P-gp structure also reveals interesting differences with MsbA. These differences mainly concern the size and charge of the internal chamber which is delimited by the half-barrels of the TMDs and ICDs of the two transporter halves. For the MsbA, the chamber is characterized by a highly positive surface potential. In P-gp, while the surface potential remains globally positive it is much weaker than in MsbA. Also, due to the presence of several bulky aromatic residues, the volume of the P-gp chamber interior is significantly reduced as compared to MsbA. Such differences can be associated with the distinct selectivity of the two ABC transporters. MsbA is known to transport lipid A, a bulky molecule made of 7 hydrophobic chains linked to a disaccharide. It can be evaluated that the molecular volume of lipid A is more that twice that of vinblastine, a typical P-gp substrate. Furthermore, lipid A contains two negatively charged phosphate groups. On the other hand no definite charge selectivity exists for molecules transported by P-gp. While selectivity for cations was initially assumed, a preference for molecules containing electron donor groups seems to occur [59] . The existence of such a correlation between size and charge of the transported molecule and cavity structure gives further support to the proposal [10] that the chamber is involved in lipid or drug binding from the inner bilayer leaflet. There is a spectacular contribution of aromatic residues to the chamber. Interestingly, an early molecular modeling study of P-gp already emphasized the possible importance of TM helix aromatic residues in transport by P-gp [60] . The chamber aromatic residues appear to be highly conserved not only in P-gps but also in phosphatidylcholine translocase and also to a large extent in bile salt export pumps. These suggest an important general role in the transport process which is not related to the very selectivity of transport (although, as already suggested [60] , stacking interactions may be important in the case of the numerous aromatic drugs transported by P-gp). Chamber aromatic residues might be important for size selection and proper positioning of substrates for the transport.
Consistently, mutational replacement of several of the chamber aromatic residues is known to reduce or abolish P-gp activity [42] [43] [44] 61] . In all, the conservation of specific residues in the chamber among various MDR proteins as well as the correlation between the properties of the chamber and the transported molecules in P-gp and MsbA suggest that this structure plays an important role in transport by drug-lipid ABC transporters. 
Putative open and closed conformations of P-gp
While the MsbA crystallographic structure, and therefore the modeled P-gp structure, are in agreement with the presence of a bilayer accessible chamber observed by single particle EM [9] , these cannot account for all the available structural data on P-gp. For example, the absence in the MsbA structure of an extracellular opening observed in P-gp by electron microscopy has been emphasized as well as the fact that TM helices of the two transporters halves that can be crosslinked in P-gp [62] are distant in the MsbA structure [63] . Indeed, in the P-gp open structure modeled from MsbA, we have measured that experimentally crosslinkable residues of TM6 and TM12 are located more than 4 nm apart.
Similarly, the two NBD are separated by 3.3 nm in the modeled P-gp although their crosslinking has also been reported. [64, 65] . Recently, the dimensions of the open MsbA crystal structure have been reported to be incompatible with EM studies on P-gp two-dimensional crystals [12, 13] . This led Lee et al. [12] to propose that P-gp could exist in two different forms, an open structure (similar to the MsbA crystal structure) as well as a closed structure (visualized by EM on two-dimensional crystals). These authors also suggested that the MsbA crystal structure could be made consistent with EM data on P-gp if the two monomers were rotated toward each other in order to bring the two TMDs and NBDs together into such a closed structure. However, we have measured that, if the modeled open P-gp structure is closed in such a fashion, the crosslinkable residues of TM6 and TM12 remain at distances of 3 nm or more. We have also evaluated that other recently proposed alternative dimer arrangements of the MsbA monomers [57, 66] also lead to TM6-TM12 distances from 1 to 2.5 nm when transposed to P-gp. In fact there seems to be no realistic closed association of the two P-gp halves in an MsbA crystallographic monomer-like conformation that comply with the crosslinking data.
This suggests that if, as proposed by Lee et al. [12] , P-gp can exist into both an open and a closed structure, these must be characterized not only by a different association state of the two transporters halves but also by a different intrinsic conformation of the transporter half. Indeed, crosslinking of TM6
and TM12 can only be accounted for if there is a closer association of the two halves as well as a positioning of these helices in each TMD closer to the interface between the two halves. In favor of two conformations, George and Jones [17] recently reported that the orientation of the two NBD helices α3
and α4 relative to the core domain is different in MsbA than in HisP and suggested that the former represent a different conformation of the NBD. As emphasized above, in the modeled open P-gp structure, the three ICDs interact differentially with the α-domain, the Q-loop and the core domain of the NBD. Therefore, such differences in orientation of α3 and α4 might be associated with significant differences in the relative orientations and positions of the TM helices. The occurrence of two different structures of P-gp might explain our observation that most of the residues that are known from mutagenesis and labeling experiments to be associated with the drug binding site are distinct from those inside the chamber of the modeled P-gp. Indeed, if the drug-bound state of P-gp corresponds to a conformation and association state of the 2 transporter halves different from the open structure, the TMD residues in contact with the drug are expected to be in part distinct from those of the chamber surface.
In conclusion, the present work provides an all-atom model of P-gp that might be a starting point for further structural studies. This model might be tested experimentally, e.g. by cysteine mutagenesis and disulfite crosslinking. The role of chamber aromatic residues might also be evaluated by mutagenesis.
Also, our study suggests that, although the chamber is not the drug binding site per se, it might constitute an initial selectivity or size filter. This structure might therefore be useful for screening of chemical libraries for new drugs or inhibitors. The corresponding coordinate file is available to other academic laboratories from the authors.
Table 1
Conservation of the TMD-NBD interface between MsbA and P-gp 
Q119-S423 H166-S474 homologous N809-S1117 homologous Q119-N425  H166-E476  homologous  N809-E1119  homologous   Q119-V426  H166-P477  N809-P1020   L124-L314  L171-L479  conserved  L814-L1177  conserved   I128-F429  L175-F480  homologous  L818-F1123  homologous   K328-E330  I375-S381  I1018-E1024   D329-K332  D376-H383  homologous  D1019-L1026 a identified as indicated in Experimental Procedures b residues that correspond to those of the MsbA pair in the alignment with P-gp c conserved: both residues are identical in MsbA and P-gp; homologous: both residues are of the same type in MsbA and P-gp. a number of residues that are identical or homologous to those of the human P-gp chamber in an alignment with all sequences of the subfamily.
b number of residues that are non homologous to those of the human P-gp chamber but that are conserved in all sequences of the subfamily. Interface residues are indicated by asterisks. Aliphatic, aromatic, hydroxyl Ted and small residues are respectively in white on black, white on dark gray, black on medium gray and black on light gray. 
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